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Summary
 
Acute HIV infection is associated with a vigorous immune response characterized by the prolif-
eration of selected T cell receptor V beta (BV)-expressing CD8
 
1
 
 T cells. These ‘expansions’,
which are commonly detected in the peripheral blood, can persist during chronic HIV infec-
tion and may result in the dominance of particular clones. Such clonal populations are most
consistent with antigen-driven expansions of CD8
 
1
 
 T cells. However, due to the difficulties in
studying antigen-specific T cells in vivo, it has been hard to prove that oligoclonal BV expan-
sions are actually HIV specific. The use of tetrameric major histocompatibility complex–pep-
tide complexes has recently enabled direct visualization of antigen-specific T cells ex vivo but
has not provided information on their clonal composition. We have now made use of these
tetrameric complexes in conjunction with anti-BV chain–specific monoclonal antibodies and
analysis of cytotoxic T lymphocyte lines/clones to show that chronically clonally expanded
CD8
 
1
 
 T cells are HIV specific in vivo.
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D8
 
1
 
 T cells are generally believed to play a major
protective role in the immune response to HIV infec-
tion during the primary and chronic asymptomatic phase of
infection. The appearance of HIV-specific CTLs after pri-
mary infection has been shown to be concurrent with a
dramatic fall in viral load (1). During the chronic asymp-
tomatic phase of HIV infection, there are high levels of per-
sisting HIV-specific CTLs (2–5), and there is an inverse cor-
relation between HIV-specific CTL frequency and plasma
RNA viral load (6). Strong cytotoxic responses to particular
HIV epitopes may drive selection of HIV variants with mu-
tations within the epitopes, preventing presentation or rec-
ognition of the epitope by the T cells (7, 8). The appearance
of virus escape mutants suggests that the T cell response is a
major factor influencing survival of HIV within the host.
Primary infection with HIV, SIV (simian immunodefi-
ciency virus), and EBV can stimulate a vigorous CD8
 
1
 
 T cell
response characterized by the proliferation of (oligo)clonal
populations of CD8
 
1
 
 T cells. Such clonal expansions can
be very large (9–11) and may persist with dominance of
particular clones (12, 13). The antigen specificity of persist-
ing clonally expanded CD8
 
1
 
 T cells has not been previ-
ously analyzed. The pattern of TCR rearrangement is con-
sistent with antigen-driven expansions and could correlate
with the observed high degree of HIV-specific CTL activ-
ity seen during acute and chronic infection (9, 12).
Tetrameric MHC–peptide complexes, which bind spe-
cifically to appropriate MHC–peptide-specific T cells (14)
has been used to show that the large CD8
 
1
 
 T cell expan-
sions during the acute phase of EBV and lymphocytic
choriomeningitis virus are largely antigen specific (15, 16).
However, it is not known whether the smaller CD8
 
1
 
 T
cell expansions seen during acute and chronic viral infec-
tions are composed of antigen-specific cells. To determine
whether these T cells are antigen specific we have per-
formed a longitudinal analysis of the CD8
 
1
 
 TCR reper-
toire during the chronic asymptomatic stage of HIV infec-
tion using the tetrameric MHC–peptide complexes in
combination with anti-BV chain–specific mAbs and analy-
sis of CTL lines/clones. Our results identify clonally ex-
panded T cells that are HIV specific in vivo.
 
Materials and Methods
 
Patients and Controls.
 
Peripheral blood was studied from
seven HIV-infected individuals over a period of 2 and 3 yr. HIV-
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uninfected individuals, 
 
,
 
35-yr-old, were used as controls. Three
patients were studied in detail: patient 003 (HLA A2, A3, B7,
B51), a long term nonprogressor; patient 868 (HLA A2, A24,
B27, B35), a progressor; and patient 065 (HLA A1, A2, B8, B44),
a slow progressor.
 
Isolation and Fractionation of Lymphocyte Preparations.
 
PBMCs were
isolated from peripheral blood by Ficoll-Hypaque density gradi-
ent centrifugation. CD8
 
1
 
 T cells were negatively selected from
PBMCs using anti-CD4 conjugated dynabeads (Dynal UK Ltd.,
Wirral, UK). A2-Gag–specific cells were selected from PBMCs
using dynabeads indirectly conjugated to HLA A2–SLYNT-
VATL complexes.
 
Cytofluorimetric Analysis.
 
Two- and three-color staining of
PBMCs and CTL lines/clones were carried out as previously
described (17) using a combination of the following: a panel of
anti–human TCR BV chain–specific mAbs, a second layer rabbit
anti–mouse directly conjugated to FITC (DAKO Ltd., High Wy-
combe, Buckinghamshire, UK), PE-conjugated (DAKO Ltd.) HLA
A2 or B27 MHC–peptide tetrameric complexes, an anti-CD8 mAb
directly conjugated to PE, and an anti-CD8 mAb directly con-
jugated to Tricolor (Caltag Labs., San Francisco, CA). The panel of
anti–human TCR BV chain–specific mAbs formed part of the
TCR antibody workshop (18) and included the following:
E2.2E7.2 (BV2); 8F10 (BV3); IMMU157 (BV5S1); MH3-2
(BV5S2); OT145 (BV6S5); 3G5D5 (BV7.1); JR2 (BV8); AMKB1-2
(BV9); S511 (BV12); H131 (BV13S1); C1 (BV17); ELL1.4 (BV20);
IG125 (BV21S3); IMMU546 (BV22); and HUT787 (BV23). The
nomenclature used for the TCR BV elements is as described by
Arden et al. (19). Samples were analyzed on a FACS
 
Ò
 
 using the
CELLQUEST software (Becton Dickinson, San Jose, CA).
 
Production of Tetrameric MHC–Peptide Complexes.
 
Soluble pep-
tide–MHC tetramers were produced as previously described (15)
for HLA A2 and HLA B27. The HLA A2 peptide ligands were
SLYNTVATL (p17Gag 77–85) and ILKEPVHGV (Pol 476–484)
(20, 21). The B27 peptide ligand was KRWIIMGLNK (p24Gag
263–272) (22).
 
Molecular Cloning and Sequencing of TCR BV Chains.
 
mRNA was
extracted and first strand cDNA synthesis was carried out as pre-
viously described (16). The cDNA was used as a template in
PCR reactions using a 3
 
9
 
 CB primer (CGTTTGTCGTCGAC-
CTCCT TCCCATTCACC) and a 5
 
9
 
 BV primer using the same
PCR conditions previously described (17). The 5
 
9
 
 BV primers
were as follows: BV3, GTCTCTAGAGAGAAGAAGAGCGC;
BV5S1, CTCGGCCCTTTATCTTTG; BV5S2, ATAAGAATG-
CGGCCGCCAGGCCCTGGGTCAGGGGCC; BV8, ATA-
AGAATGCGGCCGCCGCTACTTTAACAACAACGTTCCG;
B21S3, ATAAGAATGCGGCCGCCGCGCAGATCCTGGGAG-
AGGGCC. The PCR products were purified and cloned, and
plasmid DNA was extracted as previously described (13). Dou-
ble-stranded sequencing was performed using T7 DNA poly-
merase (Amersham Pharmacia Biotech, Little Chalfont, Bucking-
hamshire, UK).
 
Results and Discussion
 
The Chronic Asymptomatic Stage of HIV Infection Is Associ-
ated with Expansions of Specific BV Families of the CD8
 
1
 
 TCR
Repertoire.
 
To determine whether the chronic asymp-
tomatic stage of HIV infection is associated with expansions
of CD8
 
1
 
 BV families, freshly isolated PBLs from HIV-
infected individuals were analyzed using 14 human TCR
BV–specific mAbs. Seven individuals were studied, all of
whom had seroconverted at least 5 yr previously. In all
seven patients, expansions of particular TCR BV chains
were found in the CD8
 
1
 
 TCR repertoire. Results for
three individuals are shown in Table 1. Some of the expan-
sions were large: in patient 065, 11.21% of CD8
 
1
 
 T cells
expressed BV22, compared with 3.1% (
 
6
 
 1.68 SD) in the
controls. It was common to see more than one BV expan-
sion in these patients. For example, patient 868 had signifi-
cant expansions in BV13S1 and BV21S3 (Table 1). In con-
trast, the percentage of use of each BV chain by CD8
 
1
 
 T
cells from 10 healthy controls analyzed fell within a narrow
range (data not shown).
 
The CD8
 
1
 
 BV Expansions Are (Oligo)clonal and May Per-
sist for At Least 2 yr.
 
To determine whether the restricted
CD8
 
1
 
 BV T cell expansions persisted, the CD8
 
1
 
 TCR
repertoires of three patients were reanalyzed two more
times over a period of 2 or 3 yr. We found that all the BV
expansions seen in patients 868 and 065 had persisted for 2
yr, whereas the expansion seen in patient 003 had persisted
for 
 
.
 
3 yr (data not shown). In some cases, the expression
levels of the expanded CD8
 
1
 
 BV cells had increased or
showed a transient increase. For example, the BV8 expan-
sions of 7.65% seen in patient 003 transiently increased to
17.5% only to fall again to 7.5% over a period of 3 yr. In
addition, new CD8
 
1
 
 BV expansions were found in all
three patients: patient 868 exhibited a new expansion in
BV8, patient 003 had a new expansion in BV13S1, and pa-
tient 065 had a new expansion in BV8 and BV20 (data not
shown).
 
Table 1.
 
The CD8
 
1 
 
TCR Repertoire of Three HIV-infected 
Individuals during the Chronic Asymptomatic Stage of the Disease
 
TCR BV 868
 
*
 
065
 
*
 
003
 
‡
 
Controls (s.d.)
 
§
 
2 5.03
 
i
 
4.15 6.56 5.52 (1.67)
3 2.99 3.31 2.26 4.33 (2.18)
5S2 3.62 2.00 5.67 3.25 (0.83)
6S5 2.02 2.02 3.16 1.77 (1.34)
7S1 1.93 1.00 2.24 1.59 (0.79)
8 3.59 6.86
 
7.65
 
4.48 (0.94)
9 4.04 0.71 2.16 2.16 (0.63)
12 1.71 1.54 1.75 2.24 (1.13)
13S1
 
5.79 12.69
 
4.79 1.92 (1.04)
17 3.51 6.8 4.77 6.91 (2.05)
20 2.82 4.0 2.99 1.62 (0.84)
21S3
 
7.44 7.02
 
3.76 2.44 (0.43)
22 4.96
 
11.21
 
4.27 3.1 (1.68)
23 1.59 1.59 3.27 2.79 (1.35)
 
*
 
Percentage of CD8
 
1
 
 T cells in 1996.
 
‡
 
Percentage of CD8
 
1
 
 T cells in 1995.
 
i
 
Percentage of CD8
 
1
 
 T cells stained with mAbs specific for human
TCR BV chains shown. Expansions 
 
$ 
 
mean 
 
1 
 
3 SD are shown in bold.
 
§
 
Data from 10 HIV-uninfected controls. 
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To determine the clonality of these persisting expansions
we derived the sequences of the CDR3 regions of some of
the expanded TCRs. The BV21S3 expansion of 7.44%
(2.44 
 
6
 
 0.43% SD in controls) in patient 868 was clonal
with seven out of the eight transcripts being identical (Ta-
ble 2). In patient 003, the BV8 expansion of 17.5% (4.48 
 
6
 
0.94% SD in controls) was also clonal, representing 11 out
of 11 transcripts sequenced (Table 2). We derived the se-
quences of these TCR 
 
b 
 
chains 2 yr later. In patient 868,
the original BV21S3 clonotype had been replaced by a new
clonotype that had similarity to the old. The CDR3 length
of this new clonotype is identical to the old clonotype.
Furthermore, many of the amino acids in the CDR3 re-
gion are identical, and the BJ chain used is the same (Table
2). In patient 003, the BV8 clonotype was found to persist
but at a lower frequency than first found (Table 2). Thus,
(oligo)clonal CD8
 
1
 
 T cell expansions can persist during the
chronic asymptomatic stage of HIV infection for at least 2 yr.
The persistence of these oligoclonal CD8
 
1
 
 T cell expan-
sions is most consistent with them being antigen driven, al-
though a restricted TCR repertoire is not necessarily re-
lated to HIV pathogenesis, since oligoclonal expansions
have been reported in normal individuals (17, 23). Also,
BV-expanded T cells could be a result of cell division by
cross-reactive antigens or through proliferation due to cy-
tokine-mediated bystander activation (24–26). However,
oligoclonal expansions are much more common in HIV-
infected individuals than in young, healthy controls, and
recent studies using MHC–peptide tetrameric complexes
have shown that the majority of expanded CD8
 
1
 
 T cells
are antigen specific during acute EBV and lymphocytic
choriomeningitis virus infection (15, 16).
 
The Same TCRs of Cultured CTL Lines/Clones Are Ex-
panded In Vivo.
 
To determine whether these expanded
BV chains seen in the CD8
 
1
 
 TCR repertoire were HIV
specific, the BV usage of CTL lines and clones derived
from these patients were analyzed.
In some cases, the dominant BV chain used by a CTL
line was also expanded in the PBL. For example, in patient
003 the dominant receptor used by an A2-Gag–specific
CTL line was found to be BV8, which at its highest expres-
sion level represented 17.5% of the CD8
 
1
 
 T cells in this pa-
tient. In patient 868, a B27-Gag–specific CTL line primarily
used BV13S1 and again this was expanded in the PBL of
this patient. However, in some cases the dominant BV
chain used by a CTL line/clone was not expanded in the
PBLs of these patients as assessed by anti–BV-specific mAbs.
An A2-Gag–specific CTL clone derived from patient 868
was found to express the BV5S2 chain that represented be-
tween 3.62 and 4.18% of CD8
 
1
 
 T cells over the course of 2
yr in this patient and as such is not greater than three stan-
dard deviations above the mean staining of CD8
 
1
 
 BV5S2 T
cells in control populations (3.25 
 
6
 
 0.83% SD). BV5S2 was
also found to be the dominant receptor of another B27-
Gag–specific CTL line taken from this patient. In patient
065, the dominant BV receptor used by an A2-Pol–specific
CTL line was BV3, representing between 2.24 and 3.97%
of CD8
 
1
 
 T cells, and again this was not expanded in the
PBL of this patient using the above criteria (4.33 
 
6
 
 2.18%
SD in controls). An A2-Gag clone derived from patient 003
was found to express the BV5S1 chain, which made up
2.63% of CD8
 
1
 
 T cells in this patient is also not classified as
an expansion (2.98 
 
6
 
 0.92% SD in controls).
The sequences of the dominant TCR 
 
b 
 
chains used by
these CTL lines/clones were found to be monoclonal (Ta-
ble 3). The same TCR 
 
b 
 
chains were also sequenced from
the PBLs of these patients and in all cases the clonotype of
 
Table 2.
 
The Amino Acid Sequences of the CDR3 Regions of 
TCR BV Chains from CD8
 
1
 
 PBL Expansions over a Period of 2 yr
 
Patient TCR BV CDR3 BJ 1996 1998
868 21S3 CAS SLSLAVQNNEQF FG 2S1 7/8 0/10
21S3 CAS SLSLGSSDNELF FG 2S1 0/8 5/10
003 8 CAS SSDRSDQQPQH FG 1S5 11/11 4/15
 
Table 3.
 
The Amino Acid Sequences of the CDR3 Regions from CTL Lines or Clones Derived from Chronically Infected HIV Patients
 
Patient Specificity
TCR BV chain of CTL line/clone TCR In PBL
BV CDR3 BJ 1996 1998
868 A2-Gag
 
*
 
5S2 CAS SDTVSYEQY FG 2S7 7/15
 
‡
 
3.62
 
§
 
4/9
 
‡
 
4.18
 
§
 
B27-Gag 5S2 CAS TGSQPQSYEQY FG 2S7 0/15 3.62 1/9 4.18
003 A2-Gag
 
*
 
5S1 CAS SFDSGNSPLH FG 1S6 N/D N/D 7/14 2.63
A2-Gag 8 CAS SSDRSDQPQH FG 1S5 12/12 17.5 4/15 7.5
065 A2-Pol 3 CAS SFVVSPDTQY FG 1S1 N/D 3.31 3/9 3.97
 
*
 
Designates a CTL clone.
 
‡
 
The transcript frequency of the frequency of the CTL clonotype present in the PBL of each patient in 1996 and 1998.
 
§
 
Percentage of CD8
 
1
 
 T cells stained with mAbs specific for the human TCR BV chains is shown. 
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the CTL line/clone was detected in the PBL. In patient
868, the BV5S2 A2-Gag clonotype was found to be
present in the PBL in 7 out of 15 BV5S2-primed transcripts
sequenced (Table 3). The BV5S2 B27-Gag clonotype was
not found in the PBL at this time point. However, 2 yr
later the B27-Gag clonotype was present in one out of nine
transcripts sequenced from the PBLs (Table 3). In addition,
the A2-Gag clonotype was found to persist being present in
four out of nine transcripts sequenced (Table 3). In patient
003, the BV8 clonotype found in the PBL was identical to
the BV8 clone used by the A2-Gag line derived from this
patient. This BV8 clonotype also persisted 
 
.
 
1 yr later at a
lower frequency (4 out of 15 BV8 transcripts sequenced)
(Table 3). The BV5S1 clonotype of the A2-Gag–restricted
CTL clone derived from this patient was also found in the
PBLs at a frequency of 7 out of 14 BV5S1-primed tran-
scripts sequenced (Table 3). Finally, in patient 065, the
BV3 clonotype used by the A2-Pol line was found in three
out of the nine transcripts sequenced from the PBL (Table 3).
Thus, in most cases the expanded BV chains seen in the
PBLs appear to be HIV specific as shown by the presence
of the same clonotype in the PBL and CTL line/clone.
Furthermore, some of the smaller expansions, detectable
only by sequence analysis, show that analysis of TCR rep-
ertoire by the use of BV TCR–specific mAbs can be insuf-
ficient to identify clonally expanded T cell populations.
This result also suggests that the CD8
 
1
 
 TCR repertoire is
even more restricted than previously thought. This is sup-
ported by recent studies that have used CDR3 size spec-
tratyping to analyze the TCR repertoire in HIV-infected
individuals (27, 28).
 
The BV Usage of HIV-specific CD8
 
1
 
 T Cells In Vivo Di-
rectly Correlates with the BV Usage of CTL Line/Clones.
 
To determine directly the BV usage of circulating HIV-
specific CD8
 
1
 
 T cells in these patients, MHC–peptide tet-
rameric complexes were used to stain the PBL with anti-
CD8 mAb and a panel of anti–BV-specific mAbs.
In patient 868, the A2-Gag tetramer stained 1.74% of
circulating CD8
 
1
 
 T cells, of which BV5S2 made up 75%
(Fig. 1 
 
A
 
). These A2-Gag–specific cells were found to per-
sist for at least 2 yr (data not shown). The B27-Gag tet-
ramer also stained 4.32% of circulating CD8
 
1
 
 T cells from
this patient. BV13S1 made up 37% of these HIV-specific
cells, and BV5S2 made up another 22% (Fig. 1 
 
B
 
). Thus, in
this patient, the same BV receptors that dominated the
CTL lines/clones are used by the circulating HIV-specific
CD8
 
1
 
 T cells seen in vivo. In patient 065, the A2-Pol tet-
ramer stained 1.14% of circulating CD8
 
1
 
 T cells. These
HIV-specific cells all used BV3 as their TCR (Fig. 1 
 
C
 
).
Again, the same BV chain dominated the A2-Pol line de-
rived from this patient. The A2-Gag tetramer stained 3.2%
of circulating CD8
 
1
 
 T cells in patient 003. Several different
BV chains stained with tetramer-positive cells, including
BV8 and BV5S1, which stained 
 
z
 
7 and 27%, respectively
(data not shown). This is consistent with the TCR BV
chain expressed by the A2-Gag–restricted CTL line and
clone derived from this patient.
In all the patients studied, the TCR usage of the circulat-
ing HIV-specific cells were made up of the BV chains used
by the CTL lines/clones. However, some of the expanded
BV chains seen in the CD8
 
1
 
 TCR repertoire were not
used by the CTL lines/clones we analyzed, and they did
not stain with the tetrameric MHC–peptide complexes we
used. For example, patient 868 exhibited expansions in
BV5S2, BV8, BV13S1, and BV21S3, of which only BV5S2
and BV13S1 are shown to be HIV specific. One explana-
tion for this is that these expanded T cells are cytotoxic to
as yet undefined HIV epitopes. In addition, we only ana-
lyzed the A2- and B27-restricted CTL response in these
patients. The other expanded T cells could be restricted by
other MHC class I alleles expressed by the patients. The
fact that such expanded CD8
 
1
 
 T cells are oligoclonal in na-
ture is consistent with antigen-specific expansion.
Figure 1. The TCR usage of HIV-specific CD81 T cells in vivo. PBL taken from patients 868 and 003 were stained with HLA A2–SLYNTVATL
tetrameric complexes. The PBL of patient 868 was also stained with a HLA B27–KRWIIMGLNK tetrameric complex, whereas the PBL taken from
patient 065 was stained with the HLA A2–ILKEPVHGV tetramer. The tetramer was used to stain PBL in conjunction with CD8 and a panel of BV
chain–specific mAbs. In patient 868, the A2-Gag tetramer stained 1.74% of the circulating CD81 T cells, of which BV5S2 made up 75% (A). The
B27-Gag tetramer also stained 4.32% of the circulating CD81 T cells from this patient, of which BV13S1 and BV5S2 made up 37 and 22%, respectively
(B). In patient 065, the A2-Pol tetramer stained 1.14% of the circulating CD81 T cells, of which BV3 made up 100% (C).
Table 4. The BV5S2 Amino Acid Sequences of A2-Gag–specific 
Cells Sorted from 868 PBL Using an A2-Gag Tetrameric Complex
BV CDR3 BJ Frequency
5S2 CAS SDTVSYEQY FG 2S7 10/18*
5S2 CAS SLVGQGVNEQY FG 2S5 8/18
*This sequence was also used by the A2-Gag–specific CTL clone from
this patient (see Table 3).789 Wilson et al. Brief Definitive Report
The Clonotype of HIV-specific Cells In Vivo Is Identical to that
Used by CTL In Vitro. Although the HIV-specific cells in
vivo use the same TCR BV chain as the CTL lines/clones,
the clonotype of the TCR may be different. To determine
whether the BV5S2 clonotype of the A2-Gag CTL clone
present in the PBL is used by HIV-specific T cells in vivo,
A2-Gag–specific cells were sorted from the PBL of patient
868. BV5S2 sequence analysis of the A2-Gag–specific cells
revealed the presence of the same BV5S2 clonotype seen in
the CTL clone in 10 out of 18 transcripts sequenced. One
other clonotype was also present. (Table 4). Thus, the
dominant receptors used by CTL lines/clones in vitro are
expanded in the PBLs and are HIV specific.
In conclusion, we have shown that clonally expanded
populations of CD81 T cells detected by the use of anti–
human BV chain–specific mAbs and sequence analysis are
HIV specific in vivo during the chronic asymptomatic stage
of HIV infection. Thus, the majority of expanded CD81 T
cells are driven to proliferate by antigen and can persist for
more than two years.
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